Novartis, Juno Killer T-Cells Show Promise In Another Blood Cancer
The genetically altered, cancer-killing T-cells known as CARTs showed dramatic results in non-Hodgkin lymphoma as the two leading players, the Swiss drug giant Novartis and the Seattle upstart Juno Therapeutics, pushed forward with new clinical trials.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Matthew Herper Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Genetics | Lymphoma | Non-Hodgkin's Lymphoma | Pharmaceuticals